<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00494377</url>
  </required_header>
  <id_info>
    <org_study_id>8601</org_study_id>
    <secondary_id>F1J-MC-HMDD</secondary_id>
    <nct_id>NCT00494377</nct_id>
  </id_info>
  <brief_title>Duloxetine Versus Duloxetine Plus Non-Drug Therapy for Depression</brief_title>
  <official_title>Duloxetine Versus Duloxetine Plus Non-Pharmacological Intervention in the Treatment of Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine if duloxetine plus non-drug intervention is
      more effective than duloxetine alone in patients with depression.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To test whether duloxetine 60-120 mg daily, when combined with non-pharmacological intervention, is superior to duloxetine 60-120 mg daily alone, measured by remission rate (proportion of patients with HAMD17 score &lt; or = 7 at endpoint)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To test whether duloxetine 60-120 mg daily, when combined with non-pharmacological intervention, is superior to duloxetine 60-120 mg daily alone as measured by: Mean change (baseline to endpoint) on HAMD17</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To test whether duloxetine 60-120 mg daily, when combined with non-pharmacological intervention, is superior to duloxetine 60-120 mg daily alone, measured by response rates (&gt; or = 50% decrease from baseline to endpoint on HAMD17)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To test if duloxetine 60-120 mg daily + non-pharmacological intervention, is superior to duloxetine 60-120 mg daily alone, measured by HAMD17 subscales (Core, Maier, Anxiety/Somatization, Retardation/Somatization, Sleep &amp; General Somatic Symptoms item)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To test if duloxetine 60-120 mg daily + non-pharmacological intervention, is superior to duloxetine 60-120 mg daily alone, measured by mean change from baseline to endpoint on the revised Mood and Physical symptoms of Depression scale (MAP-D)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To test if duloxetine 60-120 mg daily + non-pharmacological intervention, is superior to duloxetine 60-120 mg daily alone, measured by treatment adherence as measured by the Morisky Medication Adherence Questionnaire and study drug compliance</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To test if duloxetine 60-120 mg daily + non-pharmacological intervention, is superior to duloxetine 60-120 mg daily alone, measured by Clinical Global Impression of Severity (CGI - Severity) Rating Scale</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To test if duloxetine 60-120 mg daily + non-pharmacological intervention, is superior to duloxetine 60-120 mg daily alone, measured by Patient Global Impression of Improvement (PGI - Improvement) Rating Scale</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To test if duloxetine 60-120 mg daily + non-pharmacological intervention, is superior to duloxetine 60-120 mg daily alone, measured by patient satisfaction with medication and treatment overall as measured by a Visual Analogue Scale (VAS)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To test if duloxetine 60-120 mg daily + non-pharmacological intervention, is superior to duloxetine 60-120 mg daily alone, measured by attitudes to taking medicines as measured by the Beliefs about Medicines Questionnaire (BMQ)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To test if duloxetine 60-120 mg daily + non-pharmacological intervention, is superior to duloxetine 60-120 mg daily alone, measured by Quality of Life and Health Outcome measure: EuroQol Questionnaire (EQ-5D)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To test if duloxetine 60-120 mg daily + non-pharmacological intervention, is superior to duloxetine 60-120 mg daily alone, measured by Quality of Life and Health Outcome measure: Symptom Questionnaire</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To test if duloxetine 60-120 mg daily + non-pharmacological intervention, is superior to duloxetine 60-120 mg daily alone, measured by Quality of Life and Health Outcome measure: Somatic Subscale (SQ-SS)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To test if duloxetine 60-120 mg daily + non-pharmacological intervention, is superior to duloxetine 60-120 mg daily alone, measured by Quality of Life and Health Outcome measure: 36-item Short-Form Health Survey (SF-36)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To test if duloxetine 60-120 mg daily + non-pharmacological intervention, is superior to duloxetine 60-120 mg daily alone, measured by Quality of Life and Health Outcome measure: Resource Use and Hospitalization Module</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To test if duloxetine 60-120 mg daily + non-pharmacological intervention, is superior to duloxetine 60-120 mg daily alone, measured by painful physical symptoms of depression as measured by the VAS for Pain</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate safety and tolerability of duloxetine 60-120 mg daily when combined with non-pharmacological intervention and duloxetine 60-120 mg daily alone, as measured by spontaneously reported treatment-emergent adverse events (TEAEs)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the incidence of adverse events during Study Period III (optional taper period) as measured by spontaneously reported adverse events</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To validate a revised version of the MAP-D (a novel scale for the measurement of emotional and physical symptoms of depression) in European outpatients with depression</measure>
  </secondary_outcome>
  <enrollment>940</enrollment>
  <condition>Depression</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>duloxetine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female outpatients at least 18 years of age who, in the opinion of the
             investigator, meet criteria for major depressive disorder (MDD) as defined by
             Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria.

        Exclusion Criteria:

          -  Have a previous diagnosis of bipolar disorder, schizophrenia, or other psychotic
             disorders.

          -  Serious medical illness or clinically significant laboratory abnormalities that, in
             the judgment of the investigator, are likely to require medication/
             intervention/hospitalization during the course of the study.

          -  Abnormal thyroid stimulating hormone (TSH) concentration (outside the reference range
             of the performing laboratory). Note: Patients diagnosed with hyperthyroidism or
             hypothyroidism who have been treated on a stable dose of thyroid supplement for at
             least the past 3 months, have medically appropriate TSH concentration, and are
             clinically euthyroid are allowed.

          -  Moderate or severe hepatic impairment, including but not limited to acute liver injury
             (such as hepatitis), and severe (Child-Pugh Class C) cirrhosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2007</study_first_submitted>
  <study_first_submitted_qc>June 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2007</study_first_posted>
  <last_update_submitted>June 28, 2007</last_update_submitted>
  <last_update_submitted_qc>June 28, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

